PLX5622 hemifumarate 是 PLX5622 的半富马酸盐形式，活性与 PLX5622 等效。可用于病程发展前和过程中...
PLX5622 是一种 CSF1R 抑制剂 (IC50=0.016 µM),具体选择性、口服活性和血脑屏障通透性。PLX5622 可以引起持续和特异性的小胶质细胞的消除。 规格价格库存数量 1 mg¥ 428现货 5 mg¥ 977现货 10 mg¥ 1,633现货 25 mg¥ 2,747现货
PLX5622 hemifumarate是一种药物,通过药效动力学研究表明,在临床前研究中具有以下特性: 1、在成年C57/Bl6野生型小鼠中使用PLX5622 hemifumarate(1200 ppm;饲料;持续3周或3天)治疗后,经过3天的处理后,大约损失了80%的微胶质细胞,而在经过3周的处理后,微胶质细胞减少了99%。PLX5622(3个月龄的成年C57/Bl6野生型...
and tissue-specific metabolic effects by hyperinsulinaemic鈥揺uglycaemic clamps and insulin secretion assays in mice fed a chow diet containing PLX5622 (a CSF1R inhibitor) or a control diet.Results CSF1R inhibition depleted macrophages in multiple tissues while simultaneously increasing eosinophils and...
[28,29,30,31,32,33,34,35,36,37]. Ikezu et al. found that transient depletion of microglia caused by the CSF1R inhibitor PLX5622 can improve social impairment and stereotyped repetitive behavior in autism model mice with poly I:C-simulated maternal immune activation [38]. Interestingly, ...
Another recent study showed that treatment with the CSF1R inhibitor, PLX5622, to eliminate microglia in adult Csf1r+/− mice could prevent microglial dyshomeostasis and attenuate the pathological phenotypes of Csf1r+/− mice [12]. These studies indicate that microglial dyshomeostasis is a ...
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively). 靶点活性 MET:0.14 nM , c-Fms:0.76 nM , Src:0.12 nM 体外活性 CSF1R-IN-2在SNU-5和MKN-45细胞系中以大约1-3 nM的IC50值抑制MET自磷酸化以及...
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively.
相关产品:Pexidartinib | PLX5622 | Sotuletinib | Dovitinib | GW2580 | Edicotinib | Linifanib | Pazopanib Hydrochloride | PLX647 | PRN1371 | PF 477736 | Ki20227 | Vimseltinib | OSI-930 | Chiauranib | CSF1R-IN-2 | c-Fms-IN-1 | cFMS Receptor Inhibitor II | AZD7507 | CSF1R-IN...
Pexidartinib (PLX3397) is an oral, potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit (c-Kit), and FLT3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Pexidartinib (PLX3397) induces apoptosis and necr